The stock of Immunovant Inc (IMVT) has seen a 7.06% increase in the past week, with a 3.10% gain in the past month, and a 20.15% flourish in the past quarter. The volatility ratio for the week is 3.80%, and the volatility levels for the past 30 days are at 4.50% for IMVT. The simple moving average for the last 20 days is 7.00% for IMVT stock, with a simple moving average of -20.28% for the last 200 days.
Is It Worth Investing in Immunovant Inc (NASDAQ: IMVT) Right Now?
Company’s 36-month beta value is 0.66.Analysts have differing opinions on the stock, with 9 analysts rating it as a “buy,” 3 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for IMVT is 68.57M, and currently, short sellers hold a 29.05% ratio of that floaft. The average trading volume of IMVT on July 10, 2025 was 1.39M shares.
IMVT) stock’s latest price update
The stock of Immunovant Inc (NASDAQ: IMVT) has increased by 2.37% when compared to last closing price of $16.89. Despite this, the company has experienced a 7.06% gain in its stock price over the last five trading sessions. zacks.com reported 2025-06-02 that Immunovant (IMVT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of IMVT
Many brokerage firms have already submitted their reports for IMVT stocks, with Jefferies repeating the rating for IMVT by listing it as a “Hold.” The predicted price for IMVT in the upcoming period, according to Jefferies is $20 based on the research report published on March 03, 2025 of the current year 2025.
Raymond James gave a rating of “Outperform” to IMVT, setting the target price at $36 in the report published on October 10th of the previous year.
IMVT Trading at 12.25% from the 50-Day Moving Average
After a stumble in the market that brought IMVT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.84% of loss for the given period.
Stock Fundamentals for IMVT
The net margin for Immunovant Inc stands at -2586.5. Equity return is now at value -62.46, with -57.32 for asset returns.
Based on Immunovant Inc (IMVT), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -3835.45.
When we switch over and look at the enterprise to sales, we see a ratio of 14008.66. The receivables turnover for the company is 0.08for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.16.
Conclusion
In a nutshell, Immunovant Inc (IMVT) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
